Sign in
Active, not recruitingPhase 2

Mesotherapy Treatment of Irritable Bowel Syndrome

Key facts

Who runs it
Polyclinique de l'Europe
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
27 people enrolled
Started
28 Feb 2024
Expected to end
31 Jan 2027
Type of study
Interventional
Treatments tested
  • Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate
Record updated
31 May 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patient suffering from Irritable Bowel Syndrome according to the Rome IV criteria, whose diagnosis was made by a specialist in Hepato-Gastro-Enterology,
  • Francis score >75/500, i.e. minimal, moderate or severe severity,
  • Patient who has failed conventional treatment (treatment followed for at least 1 year and not showing an improvement in symptoms)
  • Absence of risk of ongoing pregnancy in women of childbearing age, validated by a urine test during the first consultation and before treatment and each month during treatment and until 1 month after the end of treatment

Who cannot take part

  • Patient with the following medical history or current pathologies: organic gastrointestinal pathology, disabling neurological pathology, disabling psychiatric pathology
  • Recent Post Traumatic Stress Syndrome (<1 year),
  • Fibromyalgia syndrome,
  • Known allergy to medications used in mesotherapy treatment,
  • Pregnant or breastfeeding woman

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Irritable bowel syndrome (IBS) is a gastrointestinal transit disorder characterized by chronic abdominal pain and impaired transit in the absence of demonstrated organic disease. Considered a non-fatal disease, its effects relate more to quality of life, work production and health care systems.

Read full original descriptionShow less

Given the complexity of this disease, no treatment has been recognized as standard treatment. The treatment is rather focused on treating the symptoms caused (chronic pain or intestinal transit disorder). In general, therapy is considered individualized and includes lifestyle/diet modifications and pharmaceutical therapy.

Several published case studies evaluating the effect of mesotherapy on improving the severity of the disease have demonstrated an improvement in the symptoms of this syndrome. Due to the limited number of case studies and the insufficient level of evidence to conclude, our study will therefore be a before-and-after intervention study, to evaluate the effect of four mesotherapy sessions on the treatment of IBS symptoms.

The group in the trial

  • Experimental groupTreatment being tested

    Treatment: Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
31 May 2025